Insider · CIK 0001710496
Erik C. Emerson
Files at APUS (Apimeds Pharmaceuticals US, Inc.). First filing -, latest -.
In brief
Erik C. Emerson files SEC Form 4 as CEO and director at APUS (Apimeds Pharmaceuticals US, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Erik C. Emerson has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 15, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | AGrant or award Stock Option (right to buy)derivative | +215,000 | $0.00 | $0 | 215,000 | Oct 17, 2025 |
| May 16, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | AGrant or award Common Stock, par value $0.01 per share | +750,000 | $0.00 | $0 | 750,000 | May 20, 2025 |
| May 16, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | AGrant or award Stock option (right to buy)derivative | +347,279 | $0.00 | $0 | 347,279 | May 20, 2025 |
Questions about Erik C. Emerson
Answered from the filings on this page, as of the latest one.
Is Erik C. Emerson buying or selling?
Erik C. Emerson has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Erik C. Emerson's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Erik C. Emerson has 0.
Where does Erik C. Emerson file Form 4?
Erik C. Emerson has filed Form 4 at APUS (Apimeds Pharmaceuticals US, Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.